Blockchain Registration Transaction Record

Aclarion Partners with Weill Cornell to Advance Chronic Back Pain Diagnosis

Aclarion partners with Weill Cornell Medicine to expand Nociscan technology in chronic back pain research. The SaaS platform uses biomarkers & AI to pinpoint painful spinal discs.

This development matters because chronic low back pain represents one of the most widespread and debilitating health conditions globally, affecting hundreds of millions of people and costing healthcare systems billions annually. Traditional diagnostic approaches often struggle to pinpoint the exact source of disc-related pain, leading to ineffective treatments, prolonged suffering, and unnecessary procedures. Nociscan's biomarker-based approach offers a more precise, noninvasive method for identifying painful discs, potentially revolutionizing how physicians diagnose and treat this pervasive condition. The collaboration with Weill Cornell Medicine, a leading academic medical center, validates the technology's potential and accelerates its integration into mainstream spine care. For patients, this could mean more accurate diagnoses, targeted treatments, reduced trial-and-error approaches, and ultimately better pain management outcomes. The technology's ability to objectively quantify pain biomarkers represents a significant advancement beyond subjective pain reporting, potentially transforming clinical decision-making for one of healthcare's most challenging conditions.